News
What steps are companies taking to help curb AMR by manufacturing responsibly?
22 August 2023
Date
23 May 2024
What can pharma companies do to get promising antimicrobials to the frontlines of drug resistance?
In an article from the pharmaceutical news outlet, OutsourcingPharma, Liza Laws covers the launch of the Access to Medicine Foundation's latest publication on antimicrobial research and development , providing context on the drugs profiled in the report and highlighting key findings in relation to access and stewardship planning in lower- and middle-income countries (LMICs).
Direct links
The article highlights while antimicrobial resistance (AMR) constitutes a serious public health threat, especially since most large pharma companies are no longer active in antimicrobial drug research and development, a handful of projects in late-stage clinical development could make a significant impact in the fight against AMR.
The article profiles four drugs in scope of the report – namely, gepotidacin by GSK, zoliflodacin by Innoviva, cefepime-taniborbactam by Venatorx and Emblaveo by Pfizer – providing current information about each drug’s development and the diseases they target.
It also highlights the report’s insights on access planning in LMICs, mentioning that while post-trial commitments for registration were identified in five out of the 113 LMICs in the scope of the report, it is unclear whether the products will be made available in the other 108 LMICs upon initial approval.